(Q43152142)

14 November 2017

title

Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma (English)

1 reference

14 November 2017

1 reference

Ferdinand Sudbrock

1

1 reference

14 November 2017

Matthias Schmidt

2

1 reference

14 November 2017

Thorsten Simon

3

1 reference

14 November 2017

Wolfgang Eschner

4

1 reference

14 November 2017

Frank Berthold

5

1 reference

14 November 2017

Harald Schicha

6

1 reference

14 November 2017

publication date

24 February 2010

1 reference

14 November 2017

number of pages

12

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

14 November 2017

volume

37

1 reference

14 November 2017

issue

7

1 reference

14 November 2017

page(s)

1279-1290

1 reference

Molecular pharmacology of somatostatin receptor subtypes

14 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-010-1391-7

Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-010-1391-7

Scintigraphic Localization of Pheochromocytoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-010-1391-7

State of the art in nuclear medicine dose assessment

21 January 2018

1 reference

12 December 2020

[Influence of time-dose-relationships in therapeutic nuclear medicine applications on biological effectiveness of irradiation: consequences for dosimetry]

1 reference

12 December 2020

The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients

1 reference

12 December 2020

Role of 131I-metaiodobenzylguanidine in the treatment of neuroblastoma.

1 reference

12 December 2020

Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.

1 reference

12 December 2020

Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG.

1 reference

12 December 2020

Toward patient-friendly cell-level dosimetry

1 reference

12 December 2020

131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status

1 reference

12 December 2020

Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implications of the use of 123I-MIBG.

1 reference

12 December 2020

No-carrier-added synthesis of meta-[131I]iodobenzylguanidine

1 reference

12 December 2020

Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans

1 reference

12 December 2020

The diagnosis and management of malignant phaeochromocytoma and paraganglioma.

1 reference

12 December 2020

Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG.

1 reference

12 December 2020

Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study

1 reference

12 December 2020

Neuroblastoma: a disease requiring a multitude of imaging studies.

1 reference

12 December 2020

Radiation dosimetry for 131I-mIBG therapy of neuroblastoma

1 reference

12 December 2020

Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience

1 reference

12 December 2020

Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours

1 reference

12 December 2020

Established nuclear medicine techniques for tumour diagnosis (tumour SPECT): can they still compete with (18)F-FDG-PET?

1 reference

12 December 2020

[131I]MIBG as a first line treatment in advanced neuroblastoma.

1 reference

12 December 2020

Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease

1 reference

12 December 2020

[Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 2: Therapeutic procedures]

1 reference

12 December 2020

Dosimetric models and S factors for radiation doses to the bladder wall in children receiving therapeutic iodine-131-MIBG

1 reference

12 December 2020

Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children

1 reference

12 December 2020

Distribution of absorbed dose around point sources of electrons and beta particles in water and other media

1 reference

12 December 2020

[Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG]

1 reference

12 December 2020

Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 1: Diagnostic procedures

1 reference

12 December 2020

Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit

1 reference

12 December 2020

[131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects

1 reference

12 December 2020

Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.

1 reference

12 December 2020

131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma

1 reference

12 December 2020

Dosimetry for Fractionated 131I-mIBG Therapies in Patients with Primary Resistant High-Risk Neuroblastoma: Preliminary Results

1 reference

12 December 2020

Absorbed dose estimates at the cellular level for 131I.

1 reference

12 December 2020

Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry.

1 reference

12 December 2020

Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?

1 reference

12 December 2020

Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine

1 reference

12 December 2020

Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine

1 reference

12 December 2020

The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.

1 reference

12 December 2020

Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.

1 reference

12 December 2020

10.1007/S00259-010-1391-7

Identifiers

DOI

1 reference

release_5rv5tiqpdbcahkpmh64fsidz7q

14 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5rv5tiqpdbcahkpmh64fsidz7q

24 November 2022

mapped directly with Wikidata item

1 reference